Generic Claritin-D
This article was originally published in The Tan Sheet
Executive Summary
Impax Labs granted tentative approval for generic loratadine/pseudoephedrine extended-release tablets (Schering-Plough's Claritin-D 12- and 24-Hour) on May 29 and May 24, respectively. Hayward, Calif.-based company believes it was first to file for generic 12-hour formulation. Impax, a defendant in Schering's ongoing loratadine patent litigation, also has a pending ANDA for Claritin Reditabs. In December, Impax entered into an agreement granting Novartis Consumer Health exclusive rights to market an OTC generic version of Claritin to be supplied by Impax, which is in discussions with potential OTC partners for two additional generic loratadine formulations. Novartis' Geneva Pharmaceuticals is believed to be first to file for the loratadine 10 mg tablet dosage form...You may also be interested in...
Did Sarepta Need To Tell Investors About Its Vyondys 53 Dispute Resolution Request?
Attorneys say Sarepta did not have an obligation to report its appeal, particularly since winning a formal dispute filing with the US FDA is a long shot.
Sarepta’s Vyondys: Renal Toxicity Concerns That Delayed Approval Get Enhanced Postmarketing Scrutiny, Label Warning
Sarepta must perform enhanced pharmacovigilance for serious renal toxicity events and rhabdomyolysis with the Duchenne muscular dystrophy drug, which carries a label warning for renal toxicity. Approval letter includes 2024 target completion date for ESSENCE confirmatory trial.
Horizon's Teprotumumab Breezes Through US FDA Adcom, But Safety Questions Remain
Efficacy data were striking to committee members, but they want to ensure postmarketing plans gather adequate data to address safety questions.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: